Halcygen (ASX:HGN) to expand board following departure of director and COO
30 July, 2010 by Tim DeanMelbourne-based generic pharmaceutical manufacturer, Halcygen Pharmaceuticals (ASX:HGN), is seeking to add new talent to its board and senior management following the departure of Executive Director and COO, Craig Bottomley yesterday.
Patrys adds to antibody portfolio
29 July, 2010 by Staff WritersHuman antibody therapy specialists Patrys announced today that is has acquired a new anti-cancer antibody which has been shown to significantly reduce gastric and pancreatic tumours in animal models of human cancers.
Hurdles remain for Botox as a migraine treatment
28 July, 2010 by David BinningBotox was approved in the UK this month for the treatment of migraines, however, the high costs of the cosmetic treatment as well as lingering safety concerns may restrict its ability to penetrate this new market.
Biota Holdings targeting asthma market with anti-viral drug
27 July, 2010 by Staff WritersBiota Holdings today commenced a 400-member trial in the US of its anti-viral drug BTA798 on sufferers of asthma who present with cold symptoms.
QRxPharma moving closer to market with MoxDuo IR
27 July, 2010 by Staff WritersQRxPharma reported this week that it is making important progress towards gaining European regulatory approval for its dual-opioid pain treatment MoxDuo IR.
Biotechnology, R&D ignored in federal election campaign
26 July, 2010 by Tim DeanNeither side in the upcoming federal election has made any significant announcements concerning the life sciences and biotechnology, which is further undermining confidence in the biotech industry, says Mark Horsburgh, President-elect of Licensing Executives Society Australia & New Zealand (LESANZ).
Market report: Biotechs flat amid strong market
23 July, 2010 by David BinningThe Australian stock market finished the week up today for the third week in a row, buoyed by a strong lead from Wall Street overnight which fuelled investor’s appetites for local banking and mining stocks.
TGA approves Mesoblast MPC products for Australia
22 July, 2010 by David BinningRegenerative medicine specialists Mesoblast announced today that the Australian Therapeutic Goods Administration (TGA) has granted the company a license to manufacture and supply its Mesenchymal Precursor Cell (MPC) products in Australia
ANU researchers reveal new influenza target
20 July, 2010 by Tim DeanInfuenza is a tough virus to crack. Today we’re fortunate to have two neuraminidase inhibitors - oseltamivir (Tamiflu) and zanamivir (Relenza) - that are very effective at stunting the spread of influenza.
Healthscope poised to accept offer from TPG and Carlyle
20 July, 2010 by David BinningThe board of private Australian healthcare provider Healthscope has unanimously recommended shareholders accept an offer by a US consortium of $6.26 a share to buy the company.
Market Report: Lacklustre day as anxieties about U.S economy return
16 July, 2010 by David BinningThe Australian share market closed slightly down today after a lacklustre session in which investors kept to the sidelines following weak economic data out of the U.S overnight, while anticipation of a federal election being called in the next few days contributed to the subdued mood.
Approval for Movectro a game changer for MS: Datamonitor
16 July, 2010 by David BinningRussia’s approval this week of Merck Serono’s Movectro (oral cladribine) marks a major shift towards new oral treatments for multiple sclerosis (MS), according to industry analysts Datamonitor.
CSL announces new $235m biotech facility
16 July, 2010 by Staff WritersCSL announced today that it will invest $235 million over the next five years to develop a large scale biotechnology facility at its manufacturing site in Broadmeadows focussed on the late-stage development of new therapies for cancer, bleeding disorders, inflammation and infection.
Clinuvel reports strong Phase III results for Scenesse
16 July, 2010 by David BinningMelbourne biotech Clinuvel has reported positive results from a Phase III trial of its UV protection drug Scenesse in treating sufferers of the rare genetic disorder erythropoietic protoporphyria (EPP).
ChemGenex's Omapro on track for FDA approval
14 July, 2010 by Staff WritersCancer specialists ChemGenex today announced that its recent Type A Meeting with the FDA has resulted in discussions outlining a regulatory path for the approval of its Omapro (omacetaxine mepesuccinate) treatment for patients with Chronic Myeloid Leukemia (CML).
